LONDON, September 23 /PRNewswire/ --

At the 2008 SMM maritime technology exhibition this month, Northrop Grumman Corporation's (NYSE: NOC) Sperry Marine business unit will unveil the newest enhancement to its VisionMaster FT(TM) lineup of marine navigation systems -- a widescreen high-resolution display with 25 percent more viewing area.

A photo accompanying this release is available at: http://media.primezone.com/noc/

BAGNOLS-SUR-CÈZE, France, September 23 /PRNewswire/ --

- Company's Expertise in Chromogranin A Tumor Detection Marker Technology Now Applied to Universal Technique

CISBIO Bioassays, a member of IBA group and a developer and marketer of diagnostic assays for the quantification of tumor markers, announced today the launch of its chromogranin A ELISA diagnostic tool, Chromoa. This ELISA kit complements CISBIO's existing chromogranin A RIACT kit and can be used by all laboratories for the detection and monitoring of neuroendocrine tumors.

LONDON, September 23 /PRNewswire/ --

- Proven to Significantly Outperform Existing GPS Antennas

- Patented Technology Enabling Hands-Free Pedestrian Navigation

- Proven to Reduce Drain on Battery Life by More Than 10 Percent

- Small Enough to Fit in the Slimmest and Most Compact Handset Models

- Samples Available on https://samples.sarantel.com

LONDON, September 23 /PRNewswire/ --

COPENHAGEN, September 23 /PRNewswire/ --

- Summary: Genmab has Completed Recruitment of Patients in the Phase III Study of Ofatumumab in Rituximab Refractory Follicular NHL.

AMSTERDAM - Metering, Billing/CRM Europe 2008, September 23 /PRNewswire/ -- Alcatel-Lucent (Euronext Paris and NYSE: ALU) and Deutsche Telekom today announced that they launch a web-based Smart Metering user interface for the E-Metering field trial, which is running in the German city of Friedrichshafen.

BOSTON, September 23 /PRNewswire/ --

LONDON, September 23 /PRNewswire/ -- FindAdBlue.com (http://www.findadblue.com/) is pleased to announce that it will be exhibiting at the 62nd IAA Commercial Vehicles in Hannover from 25 September to 2 October 2008. The FindAdBlue.com stand will provide visitors to the show with information about diesel SCR technology and AdBlue, maps showing AdBlue availability in Europe, and advice on the ways to buy and use AdBlue. The FindAdBlue.com stand will be located in Hall 18, at A25. The sponsors of FindAdBlue.com at the 62nd IAA Commercial Vehicles are Mercedes-Benz, Renault Truck Company, Scania and Yara Air1.

MUMBAI, India, September 23 /PRNewswire/ -- Sun Pharmaceutical Industries Ltd. announced that USFDA has granted an approval for the Abbreviated New Drug Application (ANDA) to market generic Paraplatin (R), carboplatin injection.

These generic versions of carboplatin 10mg/ml injections packed in 5 ml, 15ml and 45 ml single use vials are bio-equivalent to Paraplatin (R) injections distributed by Bristol Myers Squibb Oncology/Virology.

Carboplatin injections are indicated as initial and secondary therapy in patients with advanced ovarian carcinoma.

These strengths of Paraplatin(R) Injections have annual sales of approximately USD 45 million in the US.

Paraplatin (R) is a registered trademark of Bristol Myers Squibb Company.

LONDON, September 23 /PRNewswire/ -- Enecto offers new opportunities for B2B advertisers to target and reach visitors from certain companies with specific ads. This enables B2B advertisers to dramatically improve their digital marketing effectiveness.

Enecto, one of the leading companies in Europe within marketing and sales solutions for business-to-business (B2B) companies with a web presence, is now launching a B2B targeting solution for digital marketing.

Enecto owns a proprietary database with information about companies' IP numbers as well as detailed information about the companies like number of employees, industry, turnover and geographical location. All of this information can be used for B2B targeting.

MENLO PARK, California, September 23 /PRNewswire/ --

- European Physicians Show Strong Interest in MitraClip System

Evalve, Inc., the leader in the development of devices for the percutaneous repair of cardiac valves, announced today that the first two patients have been treated with its MitraClip(R) system in Hamburg, Germany. The MitraClip system is the first commercially available device which enables a non-surgical option for patients suffering from the effects of mitral regurgitation (MR).